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In the previous issue of Critical Care, van der Sluijs and 
colleagues [1] reviewed the pathogenesis of inﬂ  uenza and 
bacterial pneumonia, particularly pneumococcal. Th  ey 
pointed out critical diﬀ  erences in pathogenesis between 
various combinations of inﬂ  uenza and bacterial pneu-
monia. Four potential syndromes are possible. Th  e  classic 
syndrome is bacterial pneumonia following an ante-
cedent inﬂ  uenza infection [2]. Bacterial pneumonia with-
out any antecedent viral infection has been associated 
with a slightly better prognosis. Increasingly, concomitant 
bacterial and inﬂ  uenza pneumonia have been described 
and, while less common, appear to have a worse prog-
nosis than sequential infection. Important pathophysio-
logic diﬀ  erences between these syndromes are illustrated 
in this review. Unexplored in their review is viral pneu-
monia without complication by bacterial pneu  monia. 
Primary inﬂ  uenza pneumonia without complication by 
bacterial pneumonia appears to be common in the 2009 
H1N1 inﬂ  uenza epidemic.
Th  e diﬃ   culty with separating these syndromes is the 
inaccuracy of etiologic diagnosis for community-acquired 
pneumonia (CAP). Th   e CDC (Centers for Disease 
Control and Prevention) has recognized this diﬃ   culty 
and conceded to report combined inﬂ  uenza  and 
pneumonia deaths since prior to 1900 [3]. Th  e cause of 
the majority of CAP cases remains undeﬁ  ned with the 
usual culture-based approach (mainly blood cultures and 
occasional sputum or more invasive respiratory cultures). 
One of the lasting eﬀ   ects of the 2009 novel H1N1 
inﬂ  uenza epidemic may be the increasing sophistication 
and availability of molecular diagnostic tests for inﬂ  uenza 
(and other respiratory viruses). During the peak of the 
epidemic, reverse transcriptase-polymerase chain reac-
tion (RT-PCR) for inﬂ  uenza was available in many large 
institutions within 8 to 12 hours of sampling. RT-PCR 
clearly is faster than culture and much more sensitive 
than the rapid inﬂ  uenza tests previously available. Th  e 
trophism for the lower respiratory tract characteristic of 
the 2009 H1N1 inﬂ  uenza virus had diagnostic implica-
tions in addition to the pathophysiologic signiﬁ  cance of 
higher incidence and severity of primary viral pneumonia 
with acute lung injury/acute respiratory distress 
syndrome [4]. Th  e diag  nostic issue was that patients 
occasionally had negative nasopharyngeal RT-PCR tests 
while lower respiratory tract samples were positive [5]. 
Th   e frequency with which this occurs with other strains 
of inﬂ  uenza or other respiratory viruses is unknown.
One caveat of the data regarding concomitant CAP is 
that viral or atypical pathogen co-infection in these 
studies was often diagnosed only by serologic conversion. 
Sequential versus concomitant inﬂ   uenza and bacterial 
pneumonia cannot be distinguished in this way. Th  ere-
fore, the diﬀ  erential eﬀ  ect on mortality and morbidity of 
concomitant versus sequential inﬂ   uenza and bacterial 
pneumonia remains somewhat unclear.
Unfortunately, molecular diagnosis of bacterial infec-
tion lags behind that of viral. Th   e best routinely available 
diagnostic aids are the BinaxNOW urinary antigens 
(Inverness Medical International, Cranﬁ  eld, UK) for both 
pneumo coccus  and  Legionella pneumophila. Th  e  pneumo-
coccal urinary antigen can increase the diagnosis of 
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Sequential or concomitant infl  uenza and bacterial 
pneumonia are two common syndromes seen in 
community-acquired pneumonia. Inadequacies of 
diagnostic testing make separating simple pneumonia 
with either bacteria or infl  uenza from concomitant 
or sequential infl  uenza with both microorganisms 
diffi   cult, although the novel 2009 H1N1 epidemic may 
improve the availability of molecular testing for viruses. 
Given the frequency of viral pneumonia and diagnostic 
limitations, empirical antivirals may be underutilized 
in community-acquired pneumonia. Thankfully, 
increasingly eff  ective vaccines appear to disrupt this 
synergistic relationship.
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© 2010 BioMed Central Ltdpneumo  coccal pneumonia by 10% to 30% in prospective 
studies. False-positives, often after a previous upper 
respiratory infection such as otitis media, limit its 
accuracy in children and HIV-positive patients. Th  e 
Legionella urinary antigen is limited to one serogroup of 
L. pneumo  phila which is neither the most common strain 
nor serotype in certain areas of the world. In addition, 
the assay picked up only 50% of cases and had almost 
mutually exclusive results compared with a Legionella 
PCR assay on sputum.
Whole-blood PCR for bacterial pathogens is generating 
increasing interest. Recent studies of the pneumococcal 
lytA gene have increased the number of patients 
diagnosed with pneumococcal disease, and quantitation 
appears to have additional prognostic signiﬁ  cance  [6]. 
Similar prognostic signiﬁ  cance of quantitative PCR has 
been demonstrated for a meningococcal gene.
Th  e result of diagnostic limitations is that most 
treatment for CAP remains empirical. Empirical anti-
biotics are the standard, but concern about delayed 
antivirals in the recent pandemic signiﬁ  cantly increased 
the use of empirical antivirals as well. Clearly, this 
strategy makes the most sense for concomitant bacterial 
and inﬂ   uenza pneumonia. Given the limitations of 
etiologic diagnosis, the beneﬁ  t of empirical antibiotics for 
occult bacterial pneumonia in patients with documented 
inﬂ  uenza is unclear. Conversely, empirical antivirals for 
culture- and urinary antigen-negative CAP patients may 
be rational since viruses may be the etiology in up to 15% 
of cases [7], with inﬂ  uenza being the most common viral 
pathogen. Th   e incidence of primary inﬂ  uenza or conco-
mitant inﬂ   uenza CAP is clearly as high as that of 
community-acquired methicillin-resistant S. aureus 
(CA-MRSA) [8] or Pseudomonas, for which empirical 
anti  biotics in the appropriate settings have been recom-
mended by guidelines [9].
Th  e good news is that prevention of one appears to 
prevent death from the other. Th  e decrease in positive 
inﬂ  uenza cultures and inﬂ  uenza-related deaths, particu-
larly among children, starting 6 to 8 weeks after the ﬁ  rst 
dose of the novel 2009 H1N1 vaccine became available is 
impressive [10]. Conversely, the pediatric conjugate 
pneumo  coccal vaccine decreased invasive pneumococcal 
disease in infants as well as their adult caregivers [11], 
even during peak years of epidemic inﬂ  uenza. Hopefully, 
higher valent and adult conjugate vaccines will soon 
become available to disrupt this lethal relationship even 
further.
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